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Tumor necrosis factor (TNFα) is a proinflammatory 
cytokine involved in the pathogenesis of inflammatory 
bowel disease (IBD). Although TNFα has been exten-
sively targeted using systemic drugs, the use of anti-
sense and small interfering RNA (siRNA) to drive down 
its expression at the site of inflammation should pro-
vide important advantages. In this study, native and 
chemically modified siRNA against TNFα was devel-
oped and characterized using a murine model of IBD. 
siRNA with 2′-O-methyl and propanediol modifications 
(siTNF- OMe-P) were resistant to nuclease degradation 
and provided better silencing efficacy in vitro as com-
pared to unmodified siRNA. Every modification reduced 
nonspecific Toll-like receptor (TLR)-mediated immuno-
modulation in human peripheral blood mononuclear 
cells (PBMC) cells. Intrarectal administration of siTNF-
OMe-P significantly ameliorated the clinical endpoints 
and histopathological severity in 5% dextran sulphate 
sodium (DSS)-treated mice as compared to unmodified 
and other chemically modified siRNAs. Differential gene 
expression assessed in  siTNF-OMe-P-treated animals 
correlated with improved colon integrity and reduced 
TLR activation as compared to all treatment groups. 
All in all, this study demonstrates that propanediol and 
2′-O-methyl modifications have profound functional 
consequences for siRNA efficacy in vivo. Consequently, 
this strategy has potential implications for therapeutic 
intervention in IBD and other diseases.
Received 6 April 2011; accepted 4 October 2011; published online  
1 November 2011. doi:10.1038/mt.2011.236
IntroductIon
The etiology and pathophysiological mechanisms of inflammatory 
bowel disease (IBD) are not completely understood. However, 
the loss of tolerance to intestinal microbiota, the activation of 
immune cells and the production of proinflammatory cytokines 
such as TNFα, interleukin-1β, interleukin-6, and interleukin-8 are 
common features of IBD. It is widely accepted that TNFα plays a 
prominent role in this process by contributing to the recruitment 
of immunocompetent cells that amplify the inflammatory response 
in T cells, macrophages, and mucosal cells.1–5 Indeed, TNFα lev-
els are increased in both serum and mucosa of IBD patients.6–9 
Furthermore, numerous studies have also shown  significantly 
increased TNFα levels in animal models of IBD (2,4,6-trinitroben-
zenesulphonic acid and dextran sulphate sodium (DSS)-induced 
colitis).10,11 TNFα also has deleterious effects on tight junctions, 
impairing barrier function, and enhancing the immune challenge 
by luminal antigens.12,13 Mucosal cells may thus be considered 
putative targets of anti-inflammatory therapy in the early phases 
of intestinal inflammation.14
Blockade of TNFα has been shown to improve or pre-
vent inflammation in both animal models11,15,16 and humans.17 
 Anti-TNFα antibodies, such as infliximab, and adalimumab, have 
proven to be efficacious against IBD in clinical trials. However, 
anti-TNFα therapies require parenteral administration at rela-
tively high doses to achieve their therapeutic effect at specific dis-
eased sites, thereby increasing the chance of adverse effects such 
as increased vulnerability of patients to intracellular pathogens,18 
lupoid reactions3 or the generation of anti-infliximab antibodies.19 
A possible association of infliximab treatment with the develop-
ment of lymphoma20 has also been suggested. Therefore, strate-
gies providing an organ-selective blockade or inhibition of TNFα 
effects should improve the safety of these biological agents.
Among alternative strategies to block TNFα locally, the use 
of antisense oligonucleotides and small interfering RNA (siRNA) 
has received some attention,15,21 whereas antisense strategies 
addressing other molecular targets of inflammation are already 
undergoing clinical trials.22,23 Although siRNA is  considerably 
more interesting than antisense as a therapeutic approach, the 
The first two authors contributed equally to this work.
Correspondence: Jose C Perales, Department of Physiological Sciences, School of Medicine, University of Barcelona, School of Medicine, Feixa llarga s/n, 
08907, Barcelona, Spain. E-mail: jperales@ub.edu or Ester Fernández, Department of Cell Biology, Physiology and Immunology, Veterinary Faculty, 
Autonomous University of Barcelona, School of Veterinary Medicine, Cerdanyola del Vallès, 08193 Barcelona, Spain. E-mail: ester.fernandez@uab.cat
Functionally Enhanced siRNA Targeting TNFα 
Attenuates DSS-induced Colitis and TLR-mediated 
Immunostimulation in Mice
Sandra M Ocampo1,2,3, Carolina Romero4, Anna Aviñó2,5, Joan Burgueño4, Miguel A Gassull6,  
Jordi Bermúdez3, Ramon Eritja1,2,5, Ester Fernandez4 and Jose C Perales3
1Institute for Advanced Chemistry of Catalonia (IQAC), Spanish Research Council (CSIC), Barcelona, Spain; 2Institute for Research in Biomedicine  
(IRB Barcelona), Barcelona, Spain; 3Department of Physiological Sciences, School of Medicine, University of Barcelona (Campus Bellvitge), Barcelona,  
Spain; 4Department of Cell Biology, Physiology and Immunology, Veterinary Faculty, Autonomous University of Barcelona, Barcelona, Spain;  
5Networking Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain; 6Health Science Research Institute,  
Germans Trias i Pujol Foundation, Badalona, Spain
Molecular Therapy  vol. 20 no. 2 feb. 2012 383
© The American Society of Gene & Cell Therapy
siRNA Intervention in Experimental Colitis
inherent instability of the RNA moiety has hindered its clinical 
development.24
The present study describes the efficacy of chemically modi-
fied siRNA in modulating IBD symptoms mediated by TNFα after 
rectal administration of a siRNA–lipoplex complex. Propanediol 
and 2′-O-methyl-modified siRNA were stable and active in vitro 
and reduced nonspecific siRNA-mediated Toll-like receptor 
(TLR) immunomodulation in human peripheral blood mono-
nuclear cells (PBMC) and the colon of diseased mice. These data 
have immediate implications for therapeutic intervention in IBD 
alone or in combination with novel oral delivery strategies.25
results
negative modulation of tnFα gene expression  
by sirnA in primary cells
Several siRNA sequences have been extensively used to down-
regulate TNFα expression. We used one such siRNA26 to verify 
its efficiency in vitro against endogenous TNFα production by 
4T1 mouse breast carcinoma cells. Our data show a substantial 
inhibition of TNFα mRNA and protein (data not shown) using 
unmodified siRNA, although this was unable to significantly 
reduce TNFα when transfected into mouse primary peritoneal 
macrophages (Figure 1a). Therefore, we studied the capacity 
of several chemically modified siRNAs (Table 1) to effectively 
silence TNFα in peritoneal macrophages. Specifically we have 
examined the biological properties of several modified siRNAs 
bearing  2′-O-methyl-RNA, locked nucleic acids (LNA), phos-
phorothioate (PS) linkages and propanediol modification at the 
3′-end.27 All these modifications have been introduced only in 
the sense or passenger strand. Figure 1 shows that the propane-
diol modification of the 3′-end and a double methylation of the 
5′-end of the sense strand of siTNF was significantly more effec-
tive at silencing endogenous TNFα than were either unmodified 
siTNF or any other chemical modifications tested: LNA, PS, OMe 
alone, or propanediol alone. Differential siRNA efficacy inside 
the cell is a balance between persistence and its ability to engage 
 RNA-induced  silencing complex. In order to study whether our 
most effective siRNA  (siTNF-OMe-P) was resistant to degrada-
tion, we subjected all the siRNAs to a degradation assay in the 
presence of 50% fetal bovine serum (Figure 1b). All modifica-
tions improved upon the stability of unmodified siRNA against 
nuclease degradation as visualized by ethidium bromide staining. 
However,  siTNF-OMe-P was significantly more resistant over 
time (at 24 hours, 52% of siRNA remained intact by densitometry 
analysis; data not shown) than all other modifications.
Therefore, we next evaluated the therapeutic efficacy of 
 siTNF-OMe-P in different cell lines expressing endogenous and 
exogenous mouse TNFα and in vivo in an animal model of colitis 
induced by 5% DSS.
sitnF administration and therapeutic efficacy  
in a dss colitis model
siTNF-OMe-P was found to be very efficacious in both HeLa and 
4T1 cells to inhibit the production of mouse TNFα as compared to 
both unmodified siTNF or siControl (Figure 2a,b). In vivo, experi-
mental rectal administration of siRNA conjugated to lipofectamine 
2000 was initiated in 5% DSS-treated mice (56 hours). Target gene 
silencing was measured in total RNA from colon extracts 16 hours 
postadministration by quantitative reverse transcriptase-PCR. 
In the experimental conditions chosen, sham control animals 
(siControl) showed several-fold increase in TNFα mRNA with 
respect to healthy mice upon exposure to 5% DSS (Figure 2c). 
By contrast, TNFα mRNA levels in siTNF-OMe-P-treated animals 
were not significantly different than healthy mice group.
We next sought to ascertain whether, in view of their improved 
performance in vitro, chemically modified siRNAs had therapeu-
tic potential as compared to unmodified siRNA. To this end, we 
treated a group of mice on days 2 and 4 using various siRNAs. 
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Figure 1 Antitumor necrosis factor (tnFα) silencing efficiency in mouse peritoneal macrophages correlates with small interfering rnA 
(sirnA) stability. (a) Mouse peritoneal macrophages were transfected with siRNA (100 nmol/l) using DOTAP. After 20 hours of transfection, cells 
were stimulated with lipopolysaccharide (LPS) (10 ng/ml) for 10 hours and protein levels were determined by enzyme-linked immunoabsorbent assay 
(ELISA) in cell supernatants. siTNF, unmodified siRNA against TNF-α; siTNF-PS-P, siRNA anti-TNF-α modified with phosphorothioate and  propanediol; 
siTNF-LNA-P, siRNA anti-TNF-α modified with LNA and propanediol; siTNF-OMe, siRNA anti-TNF-α modified with O-methyl; siTNF-OMe-P, siRNA anti-
TNFα modified with 2′-O-methyl and propanediol; siControl, negative control siRNA modified with 2′-O-methyl. The data represent the mean ± SEM, 
n = 3. +++P < 0.001 versus siControl; *P < 0.05 versus siTNF. ANOVA, Bonferroni post-hoc test. (b) siRNAs were incubated with 50% fetal bovine serum 
for the indicated amount of time (at 37 °C). Thereafter, RNAs were separated using a nondenaturing, 20% polyacrylamide gel.
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Clinical endpoints of disease were evaluated 8 days after initiat-
ing the addition of 5% DSS. Animals on 5% DSS showed a weight 
loss over the 8-day period of analysis that was unaffected by the 
nature of the treatment (data not shown). However, siTNF-OMe-P 
treatment afforded a significantly ameliorated disease activity index 
(DAI; Figure 3a) and weight-to-length colon ratio (Figure 3b). 
Indeed, colons from mice treated with siTNF-OMe-P were less 
oedematous on necropsia, suggesting reduced inflammation con-
firmed by lower myeloperoxidase (MPO) activity (Figure 3c), which 
is a marker of neutrophil infiltration into the colon. Additionally, 
both the animal survival rate and the degree of hemorrhage in the 
caecum (Supplementary Figure S3) were clearly improved in ani-
mals treated with siTNF-OMe-P, demonstrating that the beneficial 
effects observed locally on colon inflammation correlated with 
significant amelioration of the physiological state of the animal. 
Therefore, siTNF-OMe-P treatment produces significant improve-
ments in qualitative and quantitative clinical outcomes of colitis in 
treated animals, as compared to siTNF (unmodified siRNA against 
TNF-α) and siControl-treated animals. Clinical improvement was 
mirrored at the histological level (Figure 3d,e). Both inflamma-
tory infiltrates and crypt damage scores were ameliorated with 
 siTNF-OMe-P treatment. Mice exposed to DSS in their drinking 
water exhibited crypt pathology, including crypt shortening, ero-
sion of the epithelial layer, hyperplasia, and an inflammatory cell 
infiltrate in the lamina propria. These signs of disease only decreased 
in the colon of mice treated with siTNF-OMe-P.
Gene array analysis in IBd mice treated with various 
sirnAs anti-tnFα
To gain insight into the molecular mechanisms underlying the 
therapeutic benefit provided by siTNF-OMe-P in this murine 
model of colitis, we analyzed the differential gene expression 
in colitic mice treated with various modified or unmodified 
TNFα specific siRNAs and siControl (eight mice/treatment 
were  analyzed without pooling) and compared them to healthy 
animals, using a Mouse Gene ST 1.0 microarray (Affymetrix, 
Santa Clara, CA) consisting of 25,000 genes. This study 
identified circa 4,000 genes that were modulated significantly by 
the 5% DSS treatment. These genes were tagged as “pathology-
related” genes. “siRNA-specific” genes were identified for each 
treatment group as those that were differentially expressed in 
each treatment group.
A heatmap was built using all “pathology-related” genes that 
allowed for a statistical similarity test per group (Figure 4a). 
This study showed that siTNF (unmodified siRNA against TNFα) 
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Figure 2 In vitro and in vivo potency of chemically modified small 
interfering rnAs (sirnAs) against tumor necrosis factor (tnFα). (a) 
Amount of TNFα produced after 24 hours of transfection of 50 nmol/l 
of siRNAs in HeLa cells expressing mouse TNFα from an exogenous 
expression cassette. siTNF, unmodified siRNA against TNF-α;  siTNF-OMe-P, 
siRNA anti-TNF-α modified with 2′-O-methyl and propanediol; siControl, 
negative control siRNA modified with 2′-O-methyl. The data represent the 
mean ± SEM, n = 3. +++P < 0.001 versus siControl; **P < 0.01 versus 
siTNF. ANOVA, Bonferroni post-hoc test. (b) Amount of TNFα  produced 
after 24 hours of transfection of 100 nmol/l of siRNAs in 4T1 cells. The data 
represent the mean ± SEM, n = 3. ++P < 0.01 versus siControl; **P < 0.01 
versus siTNF. ANOVA, Bonferroni post-hoc test. (c) TNFα mRNA levels in 
the colon of an animal model of chronic colitis 56 hours. after rectal infu-
sion of 4 nmol of siTNF-OMe-P (n = 4) or  siControl (n = 4) conjugated with 
lipofectamine 2000. TNFα mRNA was measured by quantitative reverse 
transcriptase (qRT)-PCR and normalized with Gapdh. The data represent 
the mean ± SEM with respect to healthy mice (n = 9). Statistical analysis 
was performed using a non-parametric ANOVA with Kruskal–Wallis post-
test. **P < 0.01 versus healthy mice.
table 1 oligonucleotide sequences of sense and antisense strands 
and their chemical modifications
Modification sequence
siTNF  
(sense/antisense)
5′-GUGCCUAUGUCUCAGCCUC-dT-dT-3′
5′-GAGGCUGAGACAUAGGCAC-dT-dT-3′
siTNF-P (sense) 5′-GUGCCUAUGUCUCAGCCUC-dT-dT-(CH2)3-OH-3′
siTNF-OMe-P 
(sense)
5′-guGCCUAUGUCUCAGCCUC-dT-dT-(CH2)3-OH-3′
siTNF-PS-P 
(sense)
5′-GUGCCUAUGUCUCAGCCUC-dT*dT*(CH2)3-OH-3′
siTNF-LNA-P 
(sense)
5′-GUGCCUAUGUCUCAGCCUC-T-T-(CH2)3-OH-3′
siTNF-OMe 
(sense)
5′-guGCCUAUGUCUCAGCCUC-dT-dT-3′
siControl  
(sense/antisense)
5′-caGUCGCGUUUGCGACUGG-dT-dT-3′
5′-CCAGUCGCAAACGCGACUG-dT-dT-3′
Abbreviations: LNA, locked nucleic acid; OMe, 2′-O-methyl; PS, phosphorothioate; 
siTNF, unmodified siRNA against tumor necrosis factor.
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and siControl are related in terms of their gene modulation 
 pattern, whereas siTNF-OMe-P is closer to siTNF-OMe. Pattern-
similarity assignment correlated well with the therapeutic poten-
tial observed through objective clinical parameters (Figure 3).
Differentially expressed genes in a given treatment sub-
group were analyzed according to the Venn diagram shown in 
Figure 4b. Note that most of the genes that were significantly 
altered (500) exhibited similar regulation in siTNF-OMe and 
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Figure 3 clinical parameters of colitis in the animals treated with small interfering rnA (sirnA) antitumor necrosis factor (tnFα). Fifty 
C57BL/6 mice were administered 5% dextran sulphate sodium (DSS) in drinking water and subsequently treated on days 2 and 4 with 4 nmol of vari-
ous siRNAs. Some animals died before the end of the study and were not included in the analysis. Animals that survived up to 8 days (healthy controls, 
n = 6; siControl, n = 7; siTNF, n = 3; siTNF-OMe, n = 5; and siTNF-OMe-P = 8), were killed to sample the distal colon and perform a histopathological 
evaluation. (a) disease activity index (DAI) was evaluated from unbiased determination of rectal bleeding, feces consistency, and overall appearance. 
(b). Weight-over-length ratio of the colon. (c) Myeloperoxidase activity in colon extracts. (d) H&E stained specimens (×200). (e) Histological score 
was assessed by the Dieleman method. Error bars represent the SEM of the mean. Statistical analysis was performed by ANOVA with Bonferroni post-
hoc test. ***P < 0.001, **P < 0.01 or *P < 0.05 versus healthy mice, and +++P < 0.001, +P < 0.05 versus siControl.
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siTNF-OMe-P and were differently regulated in siControl and 
siTNF. Only 60 genes were exclusively affected by siTNF-OMe-P 
treatment (Supplementary Table S1). A heatmap of these genes 
showed strong pattern similarity with healthy controls for most 
genes (Figure 4c). Among them, several genes implicated in tissue 
repair, such as cldn-7 (claudin 7) and ssh-2, were upregulated in 
the siTNF-OMe-P group as compared to controls, whereas other 
genes present in a healthy colon epithelium (mucin1 and 2 and 
aqp4) were found to closely match the levels found in healthy 
controls. When siTNF-OMe-P treatment group was stringently 
compared pair wise against siControl or siTNF (Supplementary 
Table S1), several keratin genes, including keratin 4, were found 
to be upregulated (more than twofold induction and probability of 
differentially expressed higher than 0.95). Crabp2, upregulated by 
agents that induce keratinocyte differentiation such as retinoic acid 
was similarly upregulated, together with Ga733 (Tacstd2; murine 
epithelial glycoprotein), a protein involved in  cell-adhesion, all in 
all suggesting that siTNF-OMe-P treatment helps re-establish a 
healthy colon epithelium.
Pathways differentially enriched in colons treated 
with sitnF-oMe-P
In order to gain insight into the molecular mechanism mediating 
the therapeutic effects evidenced for siTNF-OMe-P, we performed 
a gene ontology enrichment analysis comparing siTNF-OMe-P 
and siControl (Table 2). Several pathology-related pathways 
(apoptosis, innate immune response, cytokine production, leuko-
cyte adhesion, lymph node development, etc.) were significantly 
enriched in siControl treatment but not in siTNF-OMe-P. By con-
trast, several pathways related to tissue repair and regeneration 
(cell junction, tight junction, morphogenesis of epithelium, regu-
lation of cell differentiation, etc.), and to the normal physiology 
of the colon epithelium (keratin filaments, water channel activity, 
sodium transport, amino acid transport, etc.), were significantly 
enriched in siTNF-OMe-P but not in siControl.
chemical modifications result in reduced innate 
immune system activation
SiRNA and other RNA and DNA oligonucleotides stimulate innate 
immune response through the activation of TLR7/8 and 3.28 Gene 
ontology data indicated that innate immune response pathway was 
enriched in siControl but not siTNF-OMe-P. Therefore, we aimed 
to ascertain TLR activation capacity for all siRNAs, using a TLR7/8 
response assay in PBMC. It is important to note that murine anti-
TNFα siRNAs do not inhibit the expression of h-TNFα, a marker of 
TLR activation in this assay. As shown in Figure 5a, all chemically 
modified siRNAs exhibited reduced capacity to induce h-TNFα 
release by PBMC compared to unmodified siRNA (siTNF). We 
then examined TLR gene activation in vivo by comparing the dif-
ferential expression of several TLR genes present in the gene array 
shown previously. TLR genes 2, 3, 4, 7, and 9 were significantly 
downregulated (two-way ANOVA) after siTNF-OMe-P treatment 
(Figure 5b) when compared to siTNF-treated mice, whereas 
 siTNF-OMe was ineffective (data not shown).
dIscussIon
TNFα plays a major role in inflammatory responses and has 
therefore been identified as a major therapeutic target in differ-
ent chronic inflammatory diseases, including IBD and arthritis. 
The importance of TNFα has also been demonstrated in a variety 
of animal models11,29 using wild-type and TNFα knockout mice, 
as well as in DSS-induced colitis.15 Consequently, neutralization 
of TNFα by antibodies, soluble receptors or antisense oligonucle-
otides has shown significant success in attenuating experimental 
colitis.3,15,18–21 Zhang et al.30 reported efficient silencing of TNFα 
mRNA after rectal delivery of unmodified siRNA in 5% DSS-
treated mice, although no clinical improvement was observed.
In the present study we used the same TNFα-specific siRNA 
sequence as that described by Zhang et al.,30 but added several 
chemical modifications to the molecule. Specifically, chemi-
cal modifications (LNA, 2′-O-methyl (OMe), and PS) known to 
siControl
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50023
Figure 4 differential gene expression in a 5% dextran sulphate sodium (dss) murine colitis model after specific small interfering rnA 
(sirnA) treatments. (a) Heat map of differentially expressed genes after treatment with various siRNAs. Treatments are grouped by similarity based 
on their effects on gene expression. Horizontal strips represent genes and columns show treatment protocols. The absolute-fold changes of gene 
ratio are color coded as shown in the bar below. (b) Venn diagram of significantly upregulated or downregulated genes upon treatment. Intersections 
indicate the number of differentially expressed genes in response to specific treatments. (c) Clustering analysis of genes significantly altered by treat-
ment with siTNF-OMe-P (total 60 genes). This study was conducted at the Institute of Biomedical Research of Barcelona, located in the Barcelona 
Science Park (PCB).
Molecular Therapy  vol. 20 no. 2 feb. 2012 387
© The American Society of Gene & Cell Therapy
siRNA Intervention in Experimental Colitis
improve the stability and potency of siRNA were introduced into 
the same nucleotide sequence and were compared with propane-
diol modification at the 3′-end of the siRNA, which, according 
to previous results, exhibited an improved chemical stability in 
the context of antisense delivery.31 Several studies have shown 
improved serum stability of single-stranded and double-stranded 
nucleic acids by blocking 3′-exonuclease activity, the most impor-
tant nuclease activity in serum, with modifications at the 3′-end.32 
In this study, the silencing capacity of unmodified or chemically 
modified siTNFs was first tested in mouse peritoneal macrophages. 
This study showed that among the chemical modifications intro-
duced into the siTNFs studied, propanediol modification at 
the 3′-end showed the greatest silencing capacity (Figure 1a). 
Similarly, siTNF-OMe-P was strikingly effective in the context 
of difficult to transfect cells such as 4T1 mammary carcinoma 
cells, or HeLa cells cotransfected with an expression plasmid for 
mTNFα (Figure 2a,b). The difference in efficacy could be par-
tially accounted for by increased serum stability of siTNF-OMe-P 
(Figure 1b). This assay preferentially shows double-stranded RNA 
since staining is performed with ethidium bromide. All siRNAs, 
except for siTNF-OMe-P, showed the late appearance of a second, 
faster mobility band that could represent degradation products. 
Propanediol could stabilize siTNF-OMe-P molecule by presum-
ably blocking 3′-exonuclease activity. However, it is not clear 
whether other biological variables including off-target effects, 
stimulation of cellular protective mechanisms, or RNA-induced 
silencing complex activation may be also justify successful siRNA-
mediated silencing when utilizing OMe-P modification.28
We consistently found that when 5% DSS colitic mice were 
treated with the siRNAs described in this study, only siTNF-
OMe-P was able to reduce TNFα mRNA and improve upon clini-
cal endpoints such as the DAI, colon weight/length ratio, MPO 
activity, and histopathology, as compared to unmodified siTNF, 
siTNF-OMe, or siControl. Interestingly, unmodified siTNF 
worsened animal survival and caecal inflammation under visual 
inspection (Supplementary Figure S3b) as compared to siCon-
trol. These observations are not consistent with results published 
by Zhang et al.30 using the same protocol with unmodified siRNA 
against TNFα. Authors showed an important reduction of murine 
TNFα mRNA in the distal colon of treated mice, whereas in our 
siT
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Figure 5 Modulation of toll-like receptor (tlr)-response mediated 
by small interfering rnAs (sirnAs). Differential absolute gene expres-
sion for several TLR genes was identified using an Affymetrix Mouse Gene 
ST 1.0 microarray. (a) Peripheral blood mononuclear cells (PBMC) were 
treated with various siRNAs /DOTAP (10 nmol/l) for 18 hours. Stimulation 
of innate immune response by siRNAs was monitored by measuring the 
levels of h-tumor necrosis factor (TNFα) produced by PBMC. The data 
represent the mean ± SEM, n = 3; *P < 0.05 and **P < 0.01 versus siTNF. 
Statistical analysis was performed by ANOVA with Bonferroni post-hoc 
test. (b) Changes in gene expression induced by treatment with siTNF 
and siTNF-OMe-P. Statistical analysis was performed by two-way ANOVA. 
The data represent the mean ± SEM, n = 8.
table 2 Gene ontology pathways enriched upon treatment with 
sicontrol or sitnF-oMe-PGo pathways enriched
sicontrol sitnF-oMe-P
Apoptosis 3′,5′-Cyclic-nucleotide 
phosphodiesterase activity
Basal lamina Amino acid transmembrane 
transporter activity
Cell adhesion Cell junction
Cell migration Chemokine activity
Complement activation Cytokine activity
Cytokine production Intermediate filament
DNA repair Keratin filament
Innate immune response Ligand-dependent nuclear receptor 
activity
Leukocyte adhesion Morphogenesis of an epithelium
Lymph node development Negative regulation of angiogenesis
MAPKKK cascade Regulation of cell differentiation
Positive regulation of  
interleukin-6 production
Sodium ion binding
Positive regulation of tumor  
necrosis factor production
Sodium ion transport
Regulation of apoptosis Tight junction
Vascular endothelial growth factor Water channel activity
Vasculogenesis Amino acid transmembrane 
transporter activity
Abbreviations: OMe, 2′-O-methyl; siTNF, unmodified siRNA against tumor 
necrosis factor.
Only pathways that are enriched in siControl but not in siTNF-OMe-P, or vice-
versa, are shown.
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study TNFα mRNA was not reduced as much. In several studies 
involving acute DSS colitis,33,34 complete neutralization by mAb 
against TNFα or its absence35,36 failed to block or even exacerbated 
disease parameters. This has prompted some authors.15 to suggest 
that disease protection in the acute form of DSS colitis may be 
dependent on the degree of TNFα inhibition attained. A small 
amount of TNFα may actually be protective in the early stages of 
disease development. Antisense siRNA (or low dose mAb treat-
ment) may not totally block all TNFα production and, hence, 
might improve treatment efficacy in the acute model.15
The proinflammatory action of TNFα is critical for disease ini-
tiation, whereas its anti-inflammatory activity helps to resolve the 
disease. This dual role for TNFα has also been demonstrated in the 
pathogenesis of experimental autoimmune encephalomyelitis,37 
thereby indicating that it may be beneficial to maintain certain 
levels of TNFα.
Given the lack of information regarding the mechanism 
of action by which siRNAs against TNFα might contribute to 
improving colitis, we decided to perform a whole-genome dif-
ferential expression analysis with colitic mice treated with the 
 siRNAs featured in our study. Our major interest was to gain 
insight into the genes involved in the therapeutic effects observed 
upon local siTNF-OMe-P delivery. Only 60 genes were exclu-
sively modulated by siTNF-OMe-P treatment. Most of them were 
unchanged as compared to healthy controls, and hence were 
found in normal colon epithelium. More interesting informa-
tion was obtained by analyzing the enrichment of gene ontology 
pathways in either the siTNF-OMe-P or siControl group versus 
healthy controls. Upregulated pathways present in siControl 
are also described in other studies of differential gene expres-
sion induced by DSS,1,38 and include cytokine production, innate 
immune response, lymph node development, and angiogenesis. 
None of those pathways were enriched by siTNF-OMe-P treat-
ment. Instead, several pathways related to tissue repair, normal 
colon function and chemokine modulation were observed, sug-
gesting that colon inflammation is inhibited and tissue repair is 
activated. Similar results have been found using antisense oligo-
nucleotides targeting CD40 in a 2,4,6-trinitrobenzenesulphonic 
acid inflammatory model.39 Interestingly, antisense complexes 
were also introduced using a lipoplex enema, suggesting that 
directly access to the colon epithelia is an interesting strategy for 
the treatment of colitis.
The importance of TLR activation in assessing the per-
formance of siRNA drugs has only been recognized in the last 
couple of years.28 TLR3 has been shown to mediate the protec-
tive effects of systemic poly (I:C) in DSS-induced acute colitis.40 
Interestingly, unmodified siTNF direct stimulation of TLR3 in 
the colon was not protective in our system, probably because of 
the concomitant stimulation of several proinflammatory cytok-
ines and TLRs by the unmodified siRNA. siTNF also stimulated 
the expression of TLR7/8, 2, 4, and 13, whereas siRNA chemically 
modified with OMe-P were effective in partially suppressing these 
genes. These data are in agreement with results obtained by trans-
fecting PBMC, a good model to test TLR7/8 activation,41 with 
all siRNAs. Moreover, gene array data indicated that the double 
modification 2′OMe and propanediol conferred improved TLR 
activation with respect to 2′OMe alone. It has been shown that 
incorporation of 2′OMe modifications can dramatically increase 
nuclease resistance in serum-rich environments as compared to 
unmodified double-stranded RNA.42 Additionally, and depend-
ing on the position, as few as two 2′OMe modifications can pre-
vent immune stimulation mediated through TLR-7  pathways.43 
The mechanism by which 2′OMe modification reduces immune 
stimulation is not well established. It has been suggested that 
human TLRs might be preferentially activated by pathogen-
associated RNA that contains fewer modified nucleosides than 
does host RNA.44 Addition of 2′OMe modifications to positions 1 
and 2 of the passenger strand, as in the present study, inhibited 
the incorporation of this strand into the Ago2:RNA-induced 
silencing complex, thereby reducing off-target effects by block-
ing the interaction with Ago2.45 The synergy between 2′OMe 
and propanediol modifications with respect to TLR inhibition 
has not been previously reported. Regardless of the mechanism 
of action for propanediol, our results in vivo were consistent 
with data obtained in vitro, clearly showing that  siTNF-OMe-P 
was the only treatment resulting in improved objective clinical 
endpoints in 5% DSS colitic mice. In addition, the propanediol 
and 2′-O-methyl modifications are easy and unexpensive to be 
 incorporated in RNA, yet a large benefit can be obtained with 
the use of these modifications. For these reasons, we believe the 
findings described in this study are of potential interest in the 
development of therapeutic applications of siRNAs.
In conclusion, this study has demonstrated that siTNF-OMe-P 
treatment in murine DSS colitis resulted in the reduction of the 
DAI, the colon weight/length ratio, the extent of neutrophile infil-
tration and the microscopic evidence of inflammation, findings 
which are in agreement with its silencing ability demonstrated 
both in vitro and in vivo. Furthermore, we describe the success-
ful application of chemically modified siRNA against TNFα in 
DSS-induced colitis and the differential gene expression associ-
ated with this treatment. These results will help to develop siRNA 
therapeutics for the treatment of colon inflammation.
MAterIAls And Methods
Oligoribonucleotide synthesis. Oligoribonucleotides were prepared using 
solid phase methodology. The syntheses were carried out with an Applied 
Biosystems (Foster City, CA) (Model 3400) DNA synthesizer using a 
1-μmol scale. The sense anti-TNFα sequences shown in Table 1 siTNF-P 
(sense): 5′-GUG CCU AUG UCU CAG CCU C-dT-dT-(CH2)3-OH-3′; 
siTNF-OMe-P (sense): 5′-guG CCU AUG UCU CAG CCU C-dT-dT-
(CH2)3-OH-3′; siTNF-PS-P (sense): 5′-GUG CCU AUG UCU CAG CCU 
C-dT*dT*(CH2)3-OH-3′;  siTNF-LNA-P (sense): 5′-GUG CCU AUG UCU 
CAG CCU C-T-T-(CH2)3-OH-3′) were assembled on a controlled pore 
glass support functionalized with dimethoxytrityl-propanediol46 in order 
to obtain oligoribonucleotides carrying propanediol at the 3′-end. dT 
stands for thymidine. Lower case bold letters (g, u) refer to 2′-O-methyl-
RNA units. An asterisk (*) indicates the presence of PS linkages in the 
polymer backbone, while the T  represents a thymidine where the sugar is 
modified with a LNA nucleoside. Detailed synthesis and quality control of 
oligonucleotides are provided as Supplementary Materials and Methods 
and Supplementary Figure S1. The sequences obtained from commer-
cial sources were: sense nontargeting negative control (sense sequence 
5′-caG UCG CGU UUG CGA CUG G-dT-dT-3′), antisense nontargeting 
negative control (antisense sequence 5′-CCA GUC GCA AAC GCG ACU 
G-dT-dT-3′), antisense or guide anti-TNFα: 5′-GAG GCU GAG ACA 
UAG GCA C-dT-dT-3′.
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Preparation of siRNA molecules. Modified and unmodified sense strands 
were dissolved in Tris buffer (50 mmol/l NaCl, 10 mmol/l Tris, pH 8.0) and 
annealed with equimolar amounts of the corresponding unmodified anti-
sense strand dissolved in the same buffer. The resulting solution (0.1 ml) 
was heated at 90 °C and allowed to cool slowly within 2 hours. Then 10 μl 
of 3 mol/l sodium acetate were added and the resulting siRNAs were pre-
cipitated by addition of 0.275 ml of ethanol. The sample is kept in the freeze 
overnight and centrifuged (15 minutes, 13,400g, 4 °C). The pellet is dis-
solved in the appropriate buffer and used in the silencing experiments.
The anti-TNFα siRNA has previously been shown to efficiently 
downregulate murine TNFα mRNA.26 To save resources, we only 
present data from O-methyl modified scrambled siRNA as siRNA 
control (siControl) because it is representative of results obtained with 
unmodified, O-methyl, and O-methyl-propanediol scrambled siRNA 
in vitro and in vivo (Supplementary Figure S2).
siRNA degradation assay and RNA gel electrophoresis. One microgram 
duplex of each siRNA was incubated with 50% fetal bovine serum at 37 °C. 
Samples were incubated with 1% SDS prior to be analyzed after 0 min-
ute, 1 hour, 4 hours, and 24 hours of serum incubation, by nondenaturing 
polyacrylamide gel electrophoresis. Double-stranded RNA was visualized 
using an Ethidium Bromide bath for 30 minutes. in order to determine the 
percentage of intact siRNA.
Cell culture, transfection, and cellular assays. HeLa cells were cultured 
under standard conditions. HeLa cells were transfected with 250 ng of the 
plasmid expressing murine TNFα plasmid using lipofectin (Invitrogen, 
Carlsbad, CA), following the manufacturer’s instructions. One hour after 
transfection, TNFα expressing HeLa cells were transfected with 50 nmol/l 
of each siRNA, using oligofectamine (Invitrogen). The TNFα concentra-
tion was determined from cell culture supernatant by enzyme-linked 
immunoabsorbent assay kit (BenderMedSystems, Vienna, Austria) follow-
ing the manufacturer’s instructions.
Murine 4T1 cells were cultured under standard conditions. One 
hundred nmol/l of each siRNA duplex was incubated with lipofectamine 
2000 before being added to the 4T1 cells. After 24 hours, the amount 
of TNFα produced by the cells was analyzed by enzyme-linked 
immunosorbent assay.
For peritoneal macrophage collection, healthy mice were sacrificed 
and 10-ml harvest medium was injected into their peritoneum. Fluid 
was collected after 10 minutes. The amount of harvested cells was 
adjusted (104 cells/well) and transfected with 100 nmol/l of siRNA using 
DOTAP (Roche, Mannheim, Germany), following the manufacturer’s 
instructions. After 20 hours of transfection, cells were stimulated with 
lipopolysaccharide (10 ng/ml) for 10 hours and the TNFα released in the 
supernatant was measured by enzyme-linked immunoabsorbent assay.
PBMC were obtained from human blood using Ficoll density gradient 
separation. After 3 hours incubation at 37 °C, adherent cells were transfected 
with 10 nmol/l of siRNAs for 18 hours using DOTAP (Roche), following 
the manufacturer’s instructions. Culture supernatants were then collected 
and human TNFα production upon immunostimulation was assessed by 
enzyme-linked immunoabsorbent assay (Bender MedSystems).
DSS-induced colitis model in C57BL/6 mice. Experiments were performed 
on female C57BL/6 mice (Harlan Iberica, Barcelona, Spain). Animals were 
housed under standard conditions at 22 °C and 70–80% relative humidity, 
in a 12 hours light/dark cycle. All animal procedures conformed to EU 
regulations and were approved by the local ethical committee.
Colitis was induced by addition of 5% DSS (MP Biomedicals, Santa 
Ana, CA; PM 36–50 kDa) to drinking water. Nine healthy animals (no 
DSS in drinking water) were used as noncolitic controls.
Food and drink were provided ad libitum and intake was monitored 
daily throughout the study.
In vivo administration of siRNAs. To create lipoplex siRNA prepa-
rations, 2 μl lipofectamine 2000 (Invitrogen) was mixed with 48 μl 
OptiMEM and incubated for 5 minutes, according to the manufac-
turer’s instructions. Twenty nanomolar siRNA was suspended in 50 μl 
OptiMEM were then added to this mixture and incubated at room tem-
perature for 20 minutes. This solution was immediately administered to 
rectums of anesthetized mice (4 nmol/mouse). All siRNA preparations 
were administered twice, on days 2 and 4. Each rectal administration 
consisted of a 20 μl solution of liposomal siRNA and was delivering 
using a P20 pipettor.
Evaluation of the DAI. Throughout the experiment, animals were exam-
ined daily for the following variables: general state and appearance, weight 
loss, stool consistency, and food and drink intake. DAI scores were defined 
as follows: for weight: 0, no loss; 1, up to 5%; 2, 5%–10%; 3, 10%–15%; 
and 4, >15% weight loss; for stool: 0, normal; 1, soft stool; 2, semiliquid; 3, 
diarrhea but dry tail; and 4, diarrhea with wet tail; and for bleeding: 0, no 
blood; 1, presence in stool; 2, presence in anus; and 3, gross blood. The DAI 
parameter correlates well with the histopathological evaluation of inflam-
mation and lesions in intestinal crypts.47
Colonic MPO activity. Neutrophil infiltration into tissue colon was quan-
tified by measuring MPO activity as previously described48 for use in a 
96-well plate. The change in optical density at 450 nm was measured at 
3-minutes intervals.
One unit of MPO activity was defined as the amount that degraded 
1.0 μmol of peroxide per minute at 25 °C. The results were expressed as 
U/mg wet tissue.
Histology and histological score. After flushing with cold 
 phosphate-buffered saline, a whole-length longitudinal strip was fixed 
with paraformaldehyde 4%. Haematoxylin/eosin-stained sections were 
 examined blindly and scored according to widely used criteria.49
Statistical analysis. All the data obtained were plotted and statistically 
analyzed using the software package GraphPad Prism version 5.0 for 
Windows. All treatment groups were compared using a one-way ANOVA 
and Bonferroni post-hoc test (*P < 0.05, **P < 0.01, and ***P < 0.001). Only 
significant differences among the groups are indicated in the charts.
Gene expression profiling. Sixteen hours after the second administration 
of siRNAs, the colon of treated and untreated animals was obtained for 
RNA isolation. Twenty-five nanogram total RNA was used for whole tran-
scriptome amplification (Sigma, St Louis, MO) according to manufacturer’s 
recommendations. Thirty milligram distal colon (0.8 cm from the rectum) 
from each of eight mice per group was used for RNA extraction using 
RNeasy minikit (Qiagen, Dusseldorf, Germany). Distal colon was quickly 
flash with phosphate-buffered saline before collection onto RNAlater before 
RNA extraction. Ten microgram complementary DNA were obtained after 
retrotranscription of mRNA, and subsequently fragmented, biotinylated, 
and hybridized (unpooled) to Mouse Gene ST 1.0 microarrays (Affymetrix), 
as described previously.50
Microarray data analysis. Significance analysis of microarrays and 
gene ontology functional classification were carried out as described in 
Supplementary Materials and Methods. All datasets from the array have 
been submitted to GEO (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE31906).
suPPleMentArY MAterIAl
Figure S1. Quality control of representative oligonucleotides and 
siRNAs.
Figure S2. Silencing efficiency for various chemically modified 
siControl.
Figure S3. Phenotypic changes in a DSS murine colitis model after 
specific siRNAs administration.
Table S1. Differentially expressed genes.
Materials and Methods.
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